Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
Status:
Completed
Trial end date:
2020-01-03
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to determine if Domperidone in a dose of 40 mg daily
can prevent worsening of walking ability in people secondary progressive MS. The number of
participants in this study will be 62. A maximum of 75 people with secondary progressive MS
will be included. Each patient will be followed for 12 months from inclusion. Domperidone is
a medication which has been shown to increase levels of the hormone prolactin. The best
understood function of prolactin is the stimulation of milk production in women after
delivery. However, the increase in prolactin levels seen in patients treated with standard
doses of Domperidone (in doses of up to 80mg per day) usually does not lead to clinical
symptoms. Prolactin has been shown to improve myelin repair in mice. Domperidone therefore
may also improve myelin repair in people with MS. Domperidone is currently approved in Canada
to treat slow moving bowels and nausea, for instance in patients with Parkinson's Disease or
Diabetes Mellitus, where too slowly moving bowels can cause constipation. Domperidone is
available as a tablet that is usually taken four times per day. Doses up to 80mg per day may
be used but we estimate that a dose of only 40mg daily will be needed to stimulate myelin
repair. Domperidone is usually well tolerated.